Peter Morch Eriksen

Peter Morch Eriksen currently works at Dormicor ApS, as Chairman, MTIC, as Chairman, Monsenso A, as Chairman from 2022, FluoGuide A, as Chairman from 2021, Aptashape ApS, as Chairman, Netpris GmbH, as Director, PMEconsult, as Director from 2004, PME Holding ApS, as Managing Director & Director, Nervex AS, as Director, Bioporto, Inc., as Director, Bioporto Diagnostics, Inc., as Director, Veterinary Diagnostics A, as Director, and Reponex Pharmaceuticals A, as Director.
Mr. Eriksen also formerly worked at Brüel & Kjær North America, Inc., as Chief Executive Officer from 1992 to 1997, Bioporto Diagnostics A, as Chief Executive Officer & Director from 2013 to 2021, MedicoSelskabet September 2014 ApS, as Chief Executive Officer, PNN Medical A, as Chief Executive Officer from 2008 to 2009, Sense AS, as Chief Executive Officer from 2011 to 2013, Bioporto A, as Group Chief Executive Officer from 2024 to 2025, Pharma Equity Group A, as Chairman from 2022 to 2023, MedTech Innovation Center, as Chairman from 2008 to 2019, InnoCC ApS, as Chairman, JGN 1 3-12-2018 ApS, as Chairman, Ocumove ApS, as Chairman, Biostrip ApS, as Chairman from 2022 to 2023, MyBlueLabel Compliance Services A, as Chairman from 2022 to 2023, Vitrolife A, as Director from 2008 to 2010, Veterinary Diagnostics Institute, Inc., as Director, Online Grænsehandel Group ApS, as Director, Norma AS (Norway), as Director from 2011 to 2012, Medtronic, Inc., as Vice President & General Manager-Gastroenterology from 2002 to 2003, and Deltek Danmark A, as Chief Operational Officer from 1997 to 1998.
Mr. Eriksen received his undergraduate degree from Copenhagen Business School.